Cabazitaxel is a microtubule inhibitor. Cabazitaxel binds to tubulin and promotes its assembly into microtubules while simultaneously inhibiting disassembly. This leads to the stabilization of microtubules, which results in the inhibition of mitotic and interphase cellular functions.


Recommended Dose: Kabitaxel (Cabazitaxel) - 25 mg/m2 administered every three weeks as a one-hour

intravenous infusion in combination with oral prednisone 10 mg administered daily throughout the treatment.

• Kabitaxel (Cabazitaxel) requires two dilutions prior to administration

• Use the entire contents of the accompanying diluent to achieve a concentration of 10 mg/mL

• PVC equipment should not be used

• Premedication Regimen: Administer intravenously 30 minutes before each dose of Kabitaxel (Cabazitaxel):

„ Antihistamine (dexchloropheniramine 5 mg or diphenhydramine 25 mg or equivalent antihistamine)

„ Corticosteroid (dexamethasone 8 mg or equivalent steroid)

„ H2 antagonist (ranitidine 50 mg or equivalent H2 antagonist)

Antiemetic prophylaxis (oral or intravenous) is recommended as needed.


Cabazitaxel (Kabitaxel) is a microtubule inhibitor indicated in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxelcontaining treatment regimen.

Product Information

Kabitaxel is supplied as a kit consisting of the following:

• One single-dose vial of Kabitaxel (cabazitaxel) injection: a clear yellow to brownish-yellow viscous solution of 60 mg/1.5 mL in a clear glass vial

• One single-dose vial of Diluent for Kabitaxel: a clear colorless solution of 13% (w/w) ethanol in water for injection in a clear glass vial

Both items are in a blister pack in one carton.